MET and glioblastoma: Isolated reports of success with targeting tyrosine kinase inhibitors less frequently altered in glioblastoma (PDGFRA, FGFR, and c-MET) have also been reported, but clinical results have been inconsistent, likely due to mechanisms of resistance similar to those seen in the EGFRvIII trials [132,133,134].